Oral nicorandil reduces ischemic attacks in patients with stable angina: A prospective, multicenter, open-label, randomized, controlled study



      To evaluate the efficacy and safety of oral nicorandil in coronary heart disease (CHD) patients with stable angina.


      Eligible patients were randomized 1:1 to the nicorandil or control group. Current standard antianginal treatment was continued in both groups, while the patients in the nicorandil group received an additional 12-week treatment of nicorandil (5 mg thrice daily). Primary endpoint was the number of myocardial ischemia measured by 24 h Holter after 12-week treatment. Secondary endpoints included various 24 h Holter indicators, angina occurrence, 6-min walking test (6MWT), ECG QT dispersion (QTd), safety and compliance. Clinical trial registration: NCT01396395.


      A total of 402 adult patients with stable angina were enrolled. Two hundred patients were randomized to standard therapy plus nicorandil and 202 patients to standard therapy only. The baseline characteristics of the two groups were comparable. The number of myocardial ischemia attacks after treatment was significantly lower in the nicorandil group (LSMEANS 0.896) than the control group (LSMEANS 1.782), with an adjusted ratio of 0.503 (95% CI: 0.301, 0.840; P = 0.0086). No significant differences in total myocardial ischemic burden, maximum ST-depression, longest duration of ST-depression, 6MWT, or heart rate variability were noted between the two groups. Twenty three (11.7%) of nicorandil group and 13 (6.3%) patients of control group reported at least one treatment emergent adverse event, respectively.


      Nicorandil significantly reduced the number of ischemic attacks when added to standard antianginal treatment in CHD patients with stable angina. It was well tolerated with no new safety signal identified.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to International Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Forouzanfar M.H.
        • Moran A.E.
        • Flaxman A.D.
        • Roth G.
        • Mensah G.A.
        • Ezzati M.
        • Naghavi M.
        • Murray C.J.
        Assessing the global burden of ischemic heart disease, part 2: analytic methods and estimates of the global epidemiology of ischemic heart disease in 2010.
        Glob. Heart. 2012; 7: 331-342
        • Tarkin J.M.
        • Kaski J.C.
        Pharmacological treatment of chronic stable angina pectoris.
        Clin. Med. 2013; 13: 63-70
        • WHO
        Cardiovascular disease predicted to increase in China.
        • Fihn S.D.
        • Gardin J.M.
        • Abrams J.
        • Berra K.
        • Blankenship J.C.
        • Dallas A.P.
        • Douglas P.S.
        • Foody J.M.
        • Gerber T.C.
        • Hinderliter A.L.
        • et al.
        2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
        J. Am. Coll. Cardiol. 2012; 60: e44-e164
        • Task Force M.
        • Montalescot G.
        • Sechtem U.
        • Achenbach S.
        • Andreotti F.
        • Arden C.
        • Budaj A.
        • Bugiardini R.
        • Crea F.
        • Cuisset T.
        • et al.
        2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
        Eur. Heart J. 2013; 34: 2949-3003
        • Chinese Society of Cardiology CMA
        • Editorial Board CJoC
        Guideline for diagnosis and treatment of patients with chronic stable angina (no abstract).
        Zhonghua Xin Xue Guan Bing Za Zhi. 2007; 35: 195-206
        • Fernandez S.F.
        • Tandar A.
        • Boden W.E.
        Emerging medical treatment for angina pectoris.
        Expert Opin. Emerg. Drugs. 2010; 15: 283-298
        • Gomma A.H.
        • Purcell H.J.
        • Fox K.M.
        Potassium channel openers in myocardial ischaemia: therapeutic potential of nicorandil.
        Drugs. 2001; 61: 1705-1710
        • Markham A.
        • Plosker G.L.
        • Goa K.L.
        Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects.
        Drugs. 2000; 60: 955-974
        • Ota S.
        • Nishikawa H.
        • Takeuchi M.
        • Nakajima K.
        • Nakamura T.
        • Okamoto S.
        • Setsuda M.
        • Makino K.
        • Yamakado T.
        • Nakano T.
        Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART).
        Circ. J. 2006; 70: 1099-1104
        • Abrams J.
        Nitroglycerin and long-acting nitrates in clinical practice.
        Am. J. Med. 1983; 74: 85-94
        • Carson III, C.C.
        Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors.
        Am. J. Cardiol. 2005; 96: 37M-41M
        • Danchin N.
        • Angioi M.
        • Preiss J.P.
        • Jacquemin L.
        • Houriez P.
        Betablocker therapy in acute myocardial infarction.
        Arch. Mal. Coeur Vaiss. 1998; 91: 43-47
        • Group I.S.
        Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial.
        Lancet. 2002; 359: 1269-1275
        • Parker J.D.
        • Parker J.O.
        Nitrate therapy for stable angina pectoris.
        N. Engl. J. Med. 1998; 338: 520-531
        • Tadamura E.
        • Mamede M.
        • Kubo S.
        • Toyoda H.
        • Yamamuro M.
        • Iida H.
        • Tamaki N.
        • Nishimura K.
        • Komeda M.
        • Konishi J.
        The effect of nitroglycerin on myocardial blood flow in various segments characterized by rest-redistribution thallium SPECT.
        J. Nucl. Med. 2003; 44: 745-751
        • Thadani U.
        Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure.
        Cardiovasc. Drugs Ther. 1997; 10: 735-742
        • Horinaka S.
        • Yabe A.
        • Yagi H.
        • Ishimitsu T.
        • Yamazaki T.
        • Suzuki S.
        • Kohro T.
        • Nagai R.
        • Investigators J.S.
        Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study.
        Circ. J. 2010; 74: 503-509
        • Zhu W.L.
        • Shan Y.D.
        • Guo J.X.
        • Wei J.P.
        • Yang X.C.
        • Li T.D.
        • Jia S.Q.
        • He Q.
        • Chen J.Z.
        • Wu Z.G.
        • et al.
        Double-blind, multicenter, active-controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in China.
        Circ. J. 2007; 71: 826-833
        National Institutes of Health NCI ed..
        • Kinoshita M.
        • Sakai K.
        Pharmacology and therapeutic effects of nicorandil.
        Cardiovasc. Drugs Ther. 1990; 4: 1075-1088
        • Di Somma S.
        • Liguori V.
        • Petitto M.
        • Carotenuto A.
        • Bokor D.
        • de Divitiis O.
        • de Divitiis M.
        A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris.
        Cardiovasc. Drugs Ther. 1993; 7: 119-123
        • Doring G.
        Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients.
        J. Cardiovasc. Pharmacol. 1992; 20: S74-S81
        • Guermonprez J.L.
        • Blin P.
        • Peterlongo F.
        A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris.
        Eur. Heart J. 1993; 14: 30-34
        • Taira N.
        Nicorandil as a hybrid between nitrates and potassium channel activators.
        Am. J. Cardiol. 1989; 63: 18J-24J
        • Fukuda H.
        • Luo C.S.
        • Gu X.
        • Guo L.
        • Digerness S.B.
        • Li J.
        • Pike M.M.
        The effect of K(atp)channel activation on myocardial cationic and energetic status during ischemia and reperfusion: role in cardioprotection.
        J. Mol. Cell. Cardiol. 2001; 33: 545-560
        • Miura T.
        • Liu Y.
        • Kita H.
        • Ogawa T.
        • Shimamoto K.
        Roles of mitochondrial ATP-sensitive K channels and PKC in anti-infarct tolerance afforded by adenosine A1 receptor activation.
        J. Am. Coll. Cardiol. 2000; 35: 238-245
        • Serizawa K.
        • Yogo K.
        • Aizawa K.
        • Tashiro Y.
        • Ishizuka N.
        Nicorandil prevents endothelial dysfunction due to antioxidative effects via normalisation of NADPH oxidase and nitric oxide synthase in streptozotocin diabetic rats.
        Cardiovasc. Diabetol. 2011; 10: 105
        • MHRA
        Nicorandil 10 mg and 20 mg Tablets.
        Medicines and Healthcare Products Regulatory Agency, 2010